Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort

Neurology

Volumn 49, Issue 1, 1997, Pages 229-239

  Dyck, Peter James ^a,b   Davies, Jenny L ^a   Litchy, W J ^a,c   O'Brien, P C ^b  

^a Peripheral Neuropathy Research Center   (United States)

^b MAYO CLINIC   (United States)

^c Health Partners   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CORRELATION FUNCTION; DIABETES MELLITUS; DIABETIC NEUROPATHY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NERVE CONDUCTION; PRIORITY JOURNAL; SCORING SYSTEM;

EID: 0030753606     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.49.1.229     Document Type: Article

References (35)

1. Pirart J. Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973. Diabetes Care 1978;1:168-188.
2. Pirart J. Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973. Part 2. Diabetes Care 1978;1:252-263.
3. Gregersen G. Diabetic neuropathy: influence of age, sex metabolic control, and duration of diabetes on motor conduction velocity. Neurology 1967;17:972-980.
4. Kumar S, Ashe HA, Parnell LN, et al. The prevalence of foot ulceration and its correlates in type 2 diabetic patients: a population-based study. Diabetic Med 1994;11:480-484.
5. O'Hare JA, Abuaisha F, Geoghegan M. Prevalence and forms of neuropathic morbidity in 800 diabetics. Ir Med J 1994;163: 132-135.
6. Harris M, Eastman R, Cowie C. Symptoms of sensory neuropathy in adults with NIDDM in the U.S. population. Diabetes Care 1993;16:1446-1452.
7. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329: 977-986.
8. Palumbo PJ, Elveback LR, Whisnant JP. Neurologic complications of diabetes mellitus: transient ischemic attack, stroke, and peripheral neuropathy. Adv Neurol 1978;19:593-602.
9. Franklin GM, Shetterly SM, Cohen JA, Baxter J, Hamman RF. Risk factors for distal symmetric neuropathy in NIDDM. The San Luis Valley Diabetes Study. Diabetes Care 1994;17: 1172-1177.
10. LaPorte RE, Tajima N, Dorman JS, et al. Differences between blacks and whites in the epidemiology of insulin-dependent diabetes mellitus in Allegheny County, Pennsylvania. Am J Epidemiol 1986;123:592-603.
11. Orchard TJ, Dorman JS, Maser RE, et al. Factors associated with avoidance of severe complications after 25 years of IDDM. Pittsburgh Epidemiology of Diabetes Complications Study I. Diabetes Care 1990;13:741-747.
12. Walters DP, Gatling W, Mullee MA, Hill RD. The prevalence of diabetic distal sensory neuropathy in an English community. Diabetic Med 1992;9:349-353.
13. Dyck PJ, Kratz KM, Lehman KA, et al. The Rochester Diabetic Neuropathy Study: design, criteria for types of neuropathy, selection bias, and reproducibility of neuropathic tests. Neurology 1991;41:799-807.
14. Dyck PJ. Detection, characterization, and staging of polyneuropathy: assessed in diabetics. Muscle Nerve 1988;11:21-32.
15. Dyck PJ, Kratz KM, Karnes JL, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology 1993;43: 817-824.
16. Dyck PJ, Litchy WJ, Lehman KA, Hokanson JL, Low PA, O'Brien PC. Variables influencing neuropathic endpoints: the Rochester Diabetic Neuropathy Study of Healthy Subjects (RDNS-HS). Neurology 1995;45:1115-1121.
17. Dyck PJ, Karnes JL, O'Brien PC, Litchy WJ, Low PA, Melton LJ III. The Rochester Diabetic Neuropathy Study: reassessment of tests and criteria for diagnosis and staged severity. Neurology 1992;42:1164-1170.
18. Dyck PJ, Sherman WR, Hallcher LM, et al. Human diabetic endoneurial sorbital, fructose, and myo-inositol related to sural nerve morphometry. Ann Neurol 1980;8:590-596.
19. Dyck PJ, Karnes J, O'Brien PC, Swanson CJ. Neuropathy symptom profile in health, motor neuron disease, diabetic neuropathy, and amyloidosis. Neurology 1986;36:1300-1308.
20. Dyck PJ, Litchy WJ, Kratz KM, et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 1994; 36:838-845.
21. Giannini C, Dyck PJ. Basement membrane reduplication and pericyte degeneration precede development of diabetic polyneuropathy and are associated with its severity. Ann Neurol 1995;37:498-504.
22. Dyck PJ, Karnes JL, Daube J, O'Brien P, Service FJ. Clinical and neuropathological criteria for the diagnosis and staging of diabetic neuropathy. Brain 1985;108:861-880.
23. San Antonio Conference. Proceedings of a consensus development conference on standardized measures in diabetic neuropathy. Neurology 1992;42:1823-1839.
24. O'Brien PC, Dyck PJ. Procedures for setting normal values. Neurology 1995;45:17-23.
25. Dyck PJ. Quantitative sensory testing: a consensus report from the Peripheral Neuropathy Association. Neurology 1993; 43:1050-1052.
26. Dyck PJ, Zimmerman IR, Gillen DA, Johnson DM, Karnes JL, O'Brien PC. Cool, warm, and heat-pain detection thresholds: testing methods and inferences about anatomic distribution of receptors. Neurology 1993;43:1500-1508.
27. Bril V. Role of electrophysiological studies in diabetic neuropathy. Can J Neurol Sci 1994;21:S8-S12.
28. Gerr F, Letz R. Covariates of human peripheral nerve function. II. Vibrotactile and thermal thresholds. Neurotoxicol Teratol 1994;16:105-112.
29. Hillson RM, Hockaday TDR, Newton DJ. Hyperglycaemia is one correlate of deterioration in vibration sense during the 5 years after diagnosis of type 2 (non-insulin-dependent) diabetes. Diabetologia 1984;26:122-126.
30. Florkowski CM, Rowe BR, Nightingale S, Harvey TC, Barnett AH. Clinical and neurophysiological studies of aldose reductase inhibitor ponalrestat in chronic symptomatic diabetic peripheral neuropathy. Diabetes 1991;40:129-133.
31. Sorbinil Retinopathy Trial Research Group. The Sorbinil Retinopathy Trial: neuropathy results. Neurology 1993;43:1141-1149.
32. Giugliano D, Marfella R, Quatraro A, et al. Tolrestat for mild diabetic neuropathy. A 52-week, randomized, placebo-controlled trial. Ann Intern Med 1993;118:7-11.
33. Giugliano D, Acampora R, Marfella R, et al. Tolrestat in the primary prevention of diabetic neuropathy. Diabetes Care 1995;18:536-541.
34. Amthor K-F, Dahl-Jorgensen K, Berg TJ, et al. The effect of 8 years of strict glycaemic control on peripheral nerve function in IDDM patients: the Oslo Study. Diabetologia 1994;37:579-584.
35. The Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med 1995; 122:561-568.